Gilead Sciences Inc. Earnings Decline 14% In Q2

The share price is now 2.8 percent versus its SMA20, 3.36 percent versus its SMA50, and 34.14 percent versus its SMA200.

eBay Inc (NASDAQ:EBAY) is member of S&P 500 index. 3 Months Ago, the stock has been rated as “Buy” from 18 Analysts. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 16.25% since December 16, 2015 and is downtrending. Sales of its hepatitis C drugs Sovaldi and Harvoni shrank to $4 billion versus $4.9 billion in the same quarter previous year, prompting the drug company to cut its 2016 net product sales forecast to a range of $30.5 billion to $29.5 billion from $31 billion to $30 billion previously. The total traded volume was 7,374,693 shares.

Gilead Sciences is now trading at lower valuation multiples than peers such as AbbVie (ABBV), Celgene (CELG), and Amgen (AMGN).

05/31/2016 – Gilead Sciences, Inc. had its “buy” rating reiterated by analysts at Citigroup.

Gilead Sciences (NASDAQ:GILD): On Fridays trading session, Opening price of the stock was $87.32 with an intraday high of $87.44. The stock has a market capitalization of $117.93 billion and a P/E ratio of 7.56. The current price escalated 2.63% from its SMA 50 of $84.66. The biopharmaceutical company reported $3.08 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.02 by $0.06. Total revenue fell 5% year over year to $7.78 billion in the quarter. Its last’s traded volume was 1.13 million shares in comparison to its average trading volume of 1.2 million shares.

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, June 29th. Its down 0.12, from 1.21 in 2015Q4. Analyst recommendation for this stock stands at 2.50.

On July 19, 2016 Gilead Sciences, Inc. Royal Bank Of Canada reiterated a “buy” rating on shares of Gilead Sciences in a report on Saturday, April 30th. They now have a United States dollars 120 price target on the stock. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Gilead Sciences in a report on Saturday, May 14th. The company has market value of $2.04M. They now have a Dollars 125 price target on the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

In other news, Chairman John C. Martin sold 100,000 shares of the stock in a transaction on Monday, May 2nd.